Exploration of Immunology

Table 2. Representative clinical applications of immuno-materials.

Clinical trial ID	Study title	Material category	Medical condition	Study status	Results available
NCT02718625	Study of SANTYL® vs Hydrogel (SoloSite®) for Pressure Ulcers	Peptide Based Hydrogel	Pressure Ulcers	Terminated	Yes
NCT01350102	The Relationship of Hemoglobin A1c and Diabetic Wound Healing	Peptide Based Hydrogel	Diabetic Wound Healing	Terminated	Yes
NCT06561789	Remineralization Effect of βTricalcium Phosphate Nanoparticles Versus FunctionalizedβTricalcium Phosphate Nanoparticles	Functionalized Nanoparticles	Remineralization	Completed	No
NCT04277377	Nanoparticle for DSA Removal	Functionalized Nanoparticles	DSA Removal	Active, not recruiting	No
NCT04892173	JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC	Functionalized Nanoparticles	LA-HNSCC	Recruiting	No
NCT01246336	Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson’s Disease From Exhaled Breath	Functionalized Nanoparticles	Parkinson’s Disease	Completed	No
NCT05001282	A Study to Evaluate ELU001 in Patients with Solid Tumors That Overexpress Folate Receptor Alpha (FRα)	Functionalized Nanoparticles	Solid Tumors (FR overexpressing)	Terminated	No
NCT05940701	The Effectiveness of Biomimetic Materials in Preventing Enamel Demineralization During Fixed Orthodontic Treatment	Biomimetic Materials	Enamel Demineralization	Unknown status	No
NCT06717230	Digital, Conventional, And Biomimetic Approaches for Restoring Endodontically Treated Teeth	Biomimetic Materials	Endodontically Treated Teeth	Recruiting	No
NCT06473545	Retrospective Evaluation of a Novel Biomimetic Synthetic Bone Substitute (Creos® Syntogain)	Biomimetic Materials	Bone Substitute	Completed	No
NCT01305356	Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions	Biomimetic Materials	Hindfoot Fusions	Completed	Yes
NCT04328051	Influence of the Implant-prosthetic Connection in the Marginal Bone Loss and Bacterial Leakage	Biomimetic Materials	Marginal Bone Loss and Bacterial Leakage	Unknown status	No
NCT03328884	Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients (Phenomenal)	Biomimetic Materials	Brain Metastases in Breast Cancer Patients	Completed	No
NCT00389428	Multicenter Study of CPX-351(Cytarabine: Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer	Biomimetic Materials	Advanced Hematologic Cancer	Completed	No
NCT07302828	Effect of Double Nutri® Liposomal Encapsulation Technology on Human Absorption of Vitamin C and Glutathione Liquid Sachet	Biomimetic Materials	Human Absorption of Vitamin C and Glutathione	Completed	Yes
NCT01631110	Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains	Biomimetic Materials	Influenza	Completed	Yes
NCT01893177	Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)	Biomimetic Materials	Influenza	Completed	No
NCT03511820	A Post Marketing Surveillance Study of Lipo-AB^® (Amphotericin B) in Neutropenic Patients With Persistent Fever	Biomimetic Materials	Neutropenic Patients With Persistent Fever	Completed	No
NCT00697944	Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients (AMBIDEX)	Biomimetic Materials	Multiple Candida Colonization in Sepsis Patients	Unknown status	No
NCT00361842	Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer	Biomimetic Materials	Advanced Colorectal Cancer	Completed	Yes
NCT00507962	Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement	Biomimetic Materials	Advanced Cancer and Dominant Liver Involvement	Completed	No
NCT01083979	Intravesical Liposomes for Ulcerative Cystitis	Biomimetic Materials	Ulcerative Cystitis	Completed	Yes
NCT01731470	Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)	Biomimetic Materials	Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)	Completed	Yes
NCT01333423	Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)	Biomimetic Materials	Metastatic Triple Negative Breast Cancer (TNBC)	Withdrawn	No
NCT03629171	Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia	Biomimetic Materials	Relapsed, Refractory or Untreated Acute Myeloid Leukemia	Recruiting	No
NCT04526288	CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease	Biomimetic Materials	High-Grade Myeloid Cancers With Measurable Residual Disease	Terminated	Yes
NCT05627232	Tazemetostat and Palbociclib With CPX-351 for R/R AML	Biomimetic Materials	R/R AML	Recruiting	No
NCT04195945	CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients	Biomimetic Materials	Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms	Active, not recruiting	No
NCT00002147	Use of Stealth Liposomal Doxorubicin HCl (DOX-SL) in the Treatment of Moderate to Severe AIDS-Related Kaposi’s Sarcoma.	Biomimetic Materials	Moderate to Severe AIDS-Related Kaposi’s Sarcoma	Completed	No
NCT00002313	A Study of Nystatin in HIV-Infected Patients	Biomimetic Materials	AIDS-Related Kaposi’s Sarcoma	Completed	No
NCT03878199	Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms	Biomimetic Materials	Advanced Phase Myeloproliferative Neoplasms	Completed	No
NCT00002318	A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi’s Sarcoma	Biomimetic Materials	Severe AIDS-Related Kaposi’s Sarcoma	Unknown status	No
NCT00002105	Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi’s Sarcoma	Biomimetic Materials	AIDS-Related Kaposi’s Sarcoma	Completed	No
NCT00001059	Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi’s Sarcoma in Patients With AIDS	Biomimetic Materials	Kaposi’s Sarcoma in Patients With AIDS	Completed	No
NCT04933331	Early Caries Lesion Management Observational Study (ELMO)	Biomimetic Materials	Early Caries Lesion	Unknown status	No
NCT00761644	Doxil, Bevacizumab and Temsirolimus Trial	Biomimetic Materials	Not in source	Completed	No

Return to article view

Declarations

Author contributions

MT, AF, FP: Conceptualization, Writing—original draft, Writing—review & editing. AP, RR, FI, GP: Investigation, Formal analysis, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216. [DOI] [PubMed]

Tripathi AS, Zaki MEA, Al-Hussain SA, Dubey BK, Singh P, Rind L, et al. Material matters: exploring the interplay between natural biomaterials and host immune system. Front Immunol. 2023;14:1269960. [DOI] [PubMed] [PMC]

Zhong JX, Raghavan P, Desai TA. Harnessing Biomaterials for Immunomodulatory-Driven Tissue Engineering. Regen Eng Transl Med. 2023;9:224–39. [DOI] [PubMed] [PMC]

Han Y, Huang Y, Gao P, Yang Q, Jia L, Zheng Y, et al. Leptin Aggravates Periodontitis by Promoting M1 Polarization via NLRP3. J Dent Res. 2022;101:675–85. [DOI] [PubMed]

Denais CM, Gilbert RM, Isermann P, McGregor AL, te Lindert M, Weigelin B, et al. Nuclear envelope rupture and repair during cancer cell migration. Science. 2016;352:353–8. [DOI] [PubMed] [PMC]

Salthouse D, Novakovic K, Hilkens CMU, Ferreira AM. Interplay between biomaterials and the immune system: Challenges and opportunities in regenerative medicine. Acta Biomater. 2023;155:1–18. [DOI] [PubMed]

Zhang W, Zeng X, Deng X, Yang F, Ma X, Gao W. Smart biomaterials: as active immune modulators to shape pro-regenerative microenvironments. Front Cell Dev Biol. 2025;13:1669399. [DOI] [PubMed] [PMC]

Wang H, Mooney DJ. Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nat Mater. 2018;17:761–72. [DOI] [PubMed]

Biglari N, Razzaghi M, Afkham Y, Azimi G, Gross JD, Samadi A. Advanced biomaterials in immune modulation: The future of regenerative therapies. Int J Pharm. 2025;682:125972. [DOI] [PubMed]

10.

Tolikas M, Antoniou A, Ingber DE. The Wyss institute: A new model for medical technology innovation and translation across the academic-industrial interface. Bioeng Transl Med. 2017;2:247–57. [DOI] [PubMed] [PMC]

11.

Cai SS, Li T, Akinade T, Zhu Y, Leong KW. Drug delivery carriers with therapeutic functions. Adv Drug Deliv Rev. 2021;176:113884. [DOI] [PubMed] [PMC]

12.

Sridharan R, Cavanagh B, Cameron AR, Kelly DJ, O’Brien FJ. Material stiffness influences the polarization state, function and migration mode of macrophages. Acta Biomater. 2019;89:47–59. [DOI] [PubMed]

13.

McWhorter FY, Wang T, Nguyen P, Chung T, Liu WF. Modulation of macrophage phenotype by cell shape. Proc Natl Acad Sci U S A. 2013;110:17253–8. [DOI] [PubMed] [PMC]

14.

Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP/TAZ in mechanotransduction. Nature. 2011;474:179–83. [DOI] [PubMed]

15.

Tatullo M, Zavan B, Piattelli A. Critical Overview on Regenerative Medicine: New Insights into the Role of Stem Cells and Innovative Biomaterials. Int J Mol Sci. 2023;24:7936. [DOI] [PubMed] [PMC]

16.

Ben-Akiva E, Witte SE, Meyer RA, Rhodes KR, Green JJ. Polymeric micro- and nanoparticles for immune modulation. Biomater Sci. 2018;7:14–30. [DOI] [PubMed] [PMC]

17.

Xu T, Wang J, Zhao S, Chen D, Zhang H, Fang Y, et al. Accelerating the prediction and discovery of peptide hydrogels with human-in-the-loop. Nat Commun. 2023;14:3880. [DOI] [PubMed] [PMC]

18.

Hammel JH, Zatorski JM, Cook SR, Pompano RR, Munson JM. Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics. Adv Drug Deliv Rev. 2022;182:114111. [DOI] [PubMed] [PMC]

19.

Mitrovic J, Richey G, Kim S, Guler MO. Peptide Hydrogels and Nanostructures Controlling Biological Machinery. Langmuir. 2023;39:11935–45. [DOI] [PubMed] [PMC]

20.

Zhang Y, Li D, Liu Y, Peng L, Lu D, Wang P, et al. 3D-bioprinted anisotropic bicellular living hydrogels boost osteochondral regeneration via reconstruction of cartilage-bone interface. Innovation (Camb). 2023;5:100542. [DOI] [PubMed] [PMC]

21.

Wei W, Zhang Q, Zhou W, Liu Z, Wang Y, Alakpa EV, et al. Immunomodulatory application of engineered hydrogels in regenerative medicine. Appl Mater Today. 2019;14:126–36. [DOI]

22.

Xu C, Kang Y, Dong X, Jiang D, Qi M. Integration exosomes with MOF-modified multifunctional scaffold for accelerating vascularized bone regeneration. Chin Chem Lett. 2023;34:107528. [DOI]

23.

Fang J, Wang Y, Ling P, Yu D, Hu J, Wang J, et al. Microenvironment self-adaptive multifunctional hydrogels elicit immunomodulation mediated wound healing. Mater Today Bio. 2025;35:102340. [DOI] [PubMed] [PMC]

24.

Quan L, Xin Y, Wu X, Ao Q. Mechanism of Self-Healing Hydrogels and Application in Tissue Engineering. Polymers (Basel). 2022;14:2184. [DOI] [PubMed] [PMC]

25.

Kim B, Pradhan L, Hernandez A, Yenurkar D, Nethi SK, Mukherjee S. Current Advances in Immunomodulatory Biomaterials for Cell Therapy and Tissue Engineering. Adv Ther. 2023;6:2300002. [DOI]

26.

Falcone N, Ermis M, Tamay DG, Mecwan M, Monirizad M, Mathes TG, et al. Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery. Adv Healthc Mater. 2023;12:2301096. [DOI]

27.

Gil ES, O’Neill K, Aleksi E, Budrewicz J, Melidone R, Spirio L. Comparison of PuraStat self-assembling peptide hydrogel versus mineral-based Hemospray for endoscopic hemostasis of upper and lower gastrointestinal lesions in pigs. Front Gastroenterol (Lausanne). 2022;1:971353. [DOI] [PubMed] [PMC]

28.

Kasindi A, Fuchs D, Koronyo Y, Rentsendorj A, Black KL, Koronyo-Hamaoui M. Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation. Cells. 2022;11:1578. [DOI] [PubMed] [PMC]

29.

Aharoni R, Milo R, Arnon R. Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair. Pharmacol Rev. 2024;76:1133–58. [DOI] [PubMed]

30.

Münter R, Christensen E, Andresen TL, Larsen JB. Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution. Mol Ther Methods Clin Dev. 2023;29:450–9. [DOI] [PubMed] [PMC]

31.

Bo Y, Wang H. Materials-based vaccines for infectious diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022;14:e1824. [DOI] [PubMed] [PMC]

32.

Sabzi S, Habibi M, Badmasti F, Shahbazi S, Karam MRA, Farokhi M. Polydopamine-based nano adjuvant as a promising vaccine carrier induces significant immune responses against Acinetobacter baumannii-associated pneumonia. Int J Pharm. 2024;654:123961. [DOI] [PubMed]

33.

Eshaghi B, Schudel A, Sadeghi I, Chen Z, Lee AH, Kanelli M, et al. The role of engineered materials in mucosal vaccination strategies. Nat Rev Mater. 2023;9:29–45. [DOI]

34.

Yenkoidiok-Douti L, Jewell CM. Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases. ACS Biomater Sci Eng. 2020;6:759–78. [DOI] [PubMed] [PMC]

35.

Liu S, Yu J, Gan Y, Qiu X, Gao Z, Wang H, et al. Biomimetic natural biomaterials for tissue engineering and regenerative medicine: new biosynthesis methods, recent advances, and emerging applications. Mil Med Res. 2023;10:16. [DOI] [PubMed] [PMC]

36.

Lynch RI, Lavelle EC. Immuno-modulatory biomaterials as anti-inflammatory therapeutics. Biochem Pharmacol. 2022;197:114890. [DOI] [PubMed]

37.

Tu Z, Zhong Y, Hu H, Shao D, Haag R, Schirner M, et al. Design of therapeutic biomaterials to control inflammation. Nat Rev Mater. 2022;7:557–74. [DOI] [PubMed] [PMC]

38.

Vishwakarma A, Bhise NS, Evangelista MB, Rouwkema J, Dokmeci MR, Ghaemmaghami AM, et al. Engineering Immunomodulatory Biomaterials To Tune the Inflammatory Response. Trends Biotechnol. 2016;34:470–82. [DOI] [PubMed]

39.

Codispoti B, Marrelli M, Paduano F, Tatullo M. NANOmetric BIO-Banked MSC-Derived Exosome (NANOBIOME) as a Novel Approach to Regenerative Medicine. J Clin Med. 2018;7:357. [DOI] [PubMed] [PMC]

40.

Zheng D, Ruan H, Chen W, Zhang Y, Cui W, Chen H, et al. Advances in extracellular vesicle functionalization strategies for tissue regeneration. Bioact Mater. 2022;25:500–26. [DOI] [PubMed] [PMC]

41.

Farag MM. Recent trends on biomaterials for tissue regeneration applications: review. J Mater Sci. 2023;58:527–58. [DOI]

42.

Thevenot PT, Nair AM, Shen J, Lotfi P, Ko C, Tang L. The effect of incorporation of SDF-1alpha into PLGA scaffolds on stem cell recruitment and the inflammatory response. Biomaterials. 2010;31:3997–4008. [DOI] [PubMed] [PMC]

43.

Yang Y, Li J, Lei W, Wang H, Ni Y, Liu Y, et al. CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications. Int J Biol Sci. 2023;19:3341–59. [DOI] [PubMed] [PMC]

44.

de Kort BJ, Koch SE, Wissing TB, Krebber MM, Bouten CVC, Smits AIPM. Immuno-regenerative biomaterials for in situ cardiovascular tissue engineering - Do patient characteristics warrant precision engineering? Adv Drug Deliv Rev. 2021;178:113960. [DOI] [PubMed]

45.

Tatullo M, Piattelli A, Zavan B. Regenerative Medicine: Role of Stem Cells and Innovative Biomaterials 2.0. Int J Mol Sci. 2022;23:4199. [DOI] [PubMed] [PMC]

46.

Yang G, Fan X, Liu Y, Jie P, Mazhar M, Liu Y, et al. Immunomodulatory Mechanisms and Therapeutic Potential of Mesenchymal Stem Cells. Stem Cell Rev Rep. 2023;19:1214–31. [DOI] [PubMed] [PMC]

47.

Song N, Scholtemeijer M, Shah K. Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends Pharmacol Sci. 2020;41:653–64. [DOI] [PubMed] [PMC]

48.

Li H, Dai H, Li J. Immunomodulatory properties of mesenchymal stromal/stem cells: The link with metabolism. J Adv Res. 2023;45:15–29. [DOI] [PubMed] [PMC]

49.

Zhao X, Zhao Y, Sun X, Xing Y, Wang X, Yang Q. Immunomodulation of MSCs and MSC-Derived Extracellular Vesicles in Osteoarthritis. Front Bioeng Biotechnol. 2020;8:575057. [DOI] [PubMed] [PMC]

50.

Zhang S, Chuah SJ, Lai RC, Hui JHP, Lim SK, Toh WS. MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. Biomaterials. 2018;156:16–27. [DOI] [PubMed]

51.

Arellano MYG, VanHeest M, Emmadi S, Abdul-Hafez A, Ibrahim SA, Thiruvenkataramani RP, et al. Role of Mesenchymal Stem/Stromal Cells (MSCs) and MSC-Derived Extracellular Vesicles (EVs) in Prevention of Telomere Length Shortening, Cellular Senescence, and Accelerated Biological Aging. Bioengineering (Basel). 2024;11:524. [DOI] [PubMed] [PMC]

52.

Lotfy A, AboQuella NM, Wang H. Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther. 2023;14:66. [DOI] [PubMed] [PMC]

53.

Qian L, Zhang Z, Zhang R, Zheng X, Xiao B, Zhang X, et al. Activated STING-containing R-EVs from iPSC-derived MSCs promote antitumor immunity. Cancer Lett. 2024;597:217081. [DOI] [PubMed]

54.

Cone AS, Yuan X, Sun L, Duke LC, Vreones MP, Carrier AN, et al. Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer’s disease-like phenotypes in a preclinical mouse model. Theranostics. 2021;11:8129–42. [DOI] [PubMed] [PMC]

55.

Lee JH, Jeon H, Lötvall J, Cho BS. Therapeutic potential of mesenchymal stem cell-derived extracellular vesicles in SARS-CoV-2 and H1N1 influenza-induced acute lung injury. J Extracell Vesicles. 2024;13:e12495. [DOI] [PubMed] [PMC]

56.

Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol. 2008;20:86–100. [DOI] [PubMed] [PMC]